HELLP Syndrome
26
3
3
13
Key Insights
Highlights
Success Rate
87% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
7.7%
2 terminated out of 26 trials
86.7%
+0.2% vs benchmark
27%
7 trials in Phase 3/4
23%
3 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (26)
Analysis of Biological Progression and Regression of HELLP Syndrome in Time
Study of Prognostic Values of Platelet Indices and Inflammatory Markers in Patients With HELLP Syndrome.
Free DNA and Nucleosome Concentrations in Pathological Pregnancies
Pilot Project Renal and Cardiovascular Tertiary Prevention in Preeclampsia
PlacEntal Acute Atherosis RefLecting Subclinical Atherosclerosis
Preeclampsia Intervention Netherlands
The Preeclampsia Registry
Complement Regulation to Undo Systemic Harm in Preeclampsia
Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features
Pregnancy-Related Hypertension: Adherence to a New Type of Monitoring
Influence of Conditional Workout Postpartum on Arterial Stiffness Among Women With Status After Preeclampsia, Superimposed Preeclampsia or HELLP-syndrome
Evaluation of the Serum Markers sFLt1 and PlGF for the Prediction of the Complications of the Placental Vascular Pathologies in the 3rd Quarter of the Pregnancy.
Liver Disease in Pregnancy
Early Vascular Adjustments to Prevent Preeclampsia
Effectivity of Postpartum Dexamethasone for Women With Class I HELLP Syndrome
Pancreatic Stone Protein (PSP) in Pregnant Women
Correlation of Survival in Puerperae by Electrical Impedance Tomography
TTP and aHUS in Complicated Pregnancies
Women Specific Cardiac Recovery After Preeclampsia
General Anesthesia Versus Spinal Anesthesia in Patients of HELLP Syndrome